- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Hossein Kazemi on Identifying Eligible Patients With MM for De-escalation
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, discusses emerging tools to use to identify patients with multiple myeloma for de-escalating treatment.
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, speaks about emerging tools in patient assessment for de-escalation treatment for individuals with multiple myeloma.
Transcript
Are there emerging diagnostic tools for treatment de-escalation that are not widely used in practice yet that you’re expecting will help better identify patients?
It's still in research phase, in trial phase, but I'm eagerly looking forward to mass spectrometry, which can be done from peripheral blood that does not need bone marrow biopsy that makes [minimal residual disease] MRD assessment much, much easier. We can test for it more frequently, without putting the patient through the discomfort of bone marrow biopsy. Of course, it's not something that's FDA approved at this time, but I'm eagerly following the updates about that.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Oral GC Dose Tapering for MG Linked to Efgartigimod Initiation
August 25th 2025Using US claims data, the authors evaluated oral glucocorticoid (GC) use at 5 time points during their retrospective analysis: 3 months before starting efgartigimod and 3, 6, 9, and 12 months after starting efgartigimod.
Read More
